The analysis by Anthem Inc, has identified a need for more widespread implementation of these interventions aimed at reducing healthcare utilization.
Reducing unnecessary, wasteful clinical procedures and treatments is the foundation of the Choosing Wisely campaign that was initiated in 2009 by the National Physicians Alliance and funded by the American Board of Internal Medicine. The campaign has come a long way since its launch and subsequent expansion in 2012, with more than 70 lists and 400 recommendations by various medical societies on judicious use of tests, services, or medications when there would be a low value return for patients. However, a new analysis by the health plan provider Anthem has identified the need for more widespread implementation of these interventions aimed at reducing healthcare utilization.
Published in the journal JAMA Internal Medicine, the authors from Anthem Inc and its subsidiary HealthCore Inc, analyze claims data for individuals enrolled with Anthem-affiliated commercial health plans. The following services—some of the earliest of the Choosing Wisely recommendations—were selected:
When the authors analyzed the number of members who had quarterly medical and/or pharmacy claims for any of the above services over a 2- to 3-year period through 2013, they observed a decline only for 2 of the listed services: imaging for headaches (which reduced from 14.9% to 13.4%, P<.001) and cardiac imaging (which reduced from 10.8% to 9.7%, P<.001). Two of the services actually had an upward trend: use of NSAIDs for the defined conditions increased from 14.4% to 16.2% (P<.001) and HPV testing in younger women increased from 4.8% to 6.0% (P<.001).
The authors conclude that despite the statistically significant changes observed (attributed to the large sample size), they are not sure of the clinical implications of these changes, but recommend additional interventions such as data feedback, physician communication training, clinician scorecard, patient-focused strategies, and financial incentives to ensure superior impact.
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More